Press Releases Keyword Search Year None202220212020201920182017 August 26, 2022 FibroGen Announces Completion of Patient Enrollment in MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Lower Risk Transfusion-Dependent Myelodysplastic Syndromes (MDS) August 8, 2022 FibroGen Reports Second Quarter 2022 Financial Results July 25, 2022 FibroGen to Report Second Quarter 2022 Financial Results July 1, 2022 FibroGen to Participate at William Blair Biotech Focus Conference 2022 June 8, 2022 FibroGen Announces Completion of Patient Enrollment in LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Duchenne Muscular Dystrophy May 26, 2022 FibroGen to Present at Jefferies Healthcare Conference May 9, 2022 FibroGen Reports First Quarter 2022 Financial Results April 25, 2022 FibroGen to Report First Quarter 2022 Financial Results April 20, 2022 FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-1, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis February 28, 2022 FibroGen Reports Fourth Quarter and Full Year 2021 Financial Results February 14, 2022 FibroGen to Report Fourth Quarter and Full Year 2021 Financial Results February 4, 2022 FibroGen to Present at SVB Leerink 11th Annual Global Healthcare Conference January 4, 2022 FibroGen to Present at H.C. Wainwright Bioconnect Virtual Conference
